Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | AVPR2 | P30518 | 6/20 | 0.48 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14218512 | 0.83 | HTR3E (0.35) | LMNAAVPR2AVPR1AALDH1A1MEN1 | |
| SCHEMBL3459774 | 0.82 | LMNA (0.54) | LMNAAVPR2AVPR1AHSD11B1ALDH1A1 | |
| SCHEMBL3454911 | 0.82 | AVPR1A (0.62) | LMNAAVPR2AVPR1AHSD11B1ALDH1A1 | |
| SCHEMBL3454789 | 0.82 | LMNA (0.58) | LMNAAVPR2AVPR1AHSD11B1ALDH1A1 | |
| SCHEMBL3456794 | 0.81 | AVPR1A (0.52) | LMNAAVPR2AVPR1AHSD11B1ALDH1A1 | |
| SCHEMBL3456247 | 0.81 | AVPR2 (0.63) | LMNAAVPR2AVPR1AALDH1A1MEN1 | |
| SCHEMBL3455560 | 0.80 | ALDH1A1 (0.62) | LMNAAVPR2AVPR1AALDH1A1MEN1 | |
| SCHEMBL3456602 | 0.80 | ALDH1A1 (0.62) | LMNAAVPR2AVPR1AALDH1A1MEN1 | |
| SCHEMBL3455459 | 0.79 | ALDH1A1 (0.62) | LMNAAVPR2AVPR1AHSD11B1ALDH1A1 | |
| SCHEMBL3456957 | 0.79 | LMNA (0.48) | LMNAAVPR2AVPR1AHSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264414-A1 | Amide Derivatives and Pharmaceutical Use Thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264414-A1 | Amide Derivatives and Pharmaceutical Use Thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20080108598-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108598-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | LMNA 3468/4885AVPR2 902/4885AVPR1A 935/4885 |
| US-20090264414-A1 | Amide Derivatives and Pharmaceutical Use Thereof | HSD11B1, HSD11B2, HSD3B1 | LMNA 3531/4885AVPR2 835/4885AVPR1A 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.